European Heart Journal, 1994 - “Effect of Magnesium on Restenosis after percutaneous transluminal coronary angioplasty: a clinical and angiographic evaluation in a randomized patient population” (full paper)

Departments of Cardiology, Clinical Chemistry Tel Aviv Sourasky Medical Centre and the department of Mathematics and Statistics, and the Sackler School of Medicine, Tel-Aviv University, Israel. http://profmagnesium.com/PDF%27S/Effect%20of%20Mg%20on%20restenosis%201994.pdf

“CLINICAL IMPLICATION AND CONCLUSIONS

Intravenous administration of magnesium in patients undergoing coronary angioplasty is feasible and safe when applied to patients with systolic blood pressure >90 mmHg.
Adverse effects are seldom encountered and can easily be treated by the administration of fluids and temporary cessation of magnesium infusion. The rationale for the use of intravenous magnesium as adjuvant treatment during percutaneous coronary angioplasty seems to be promising.
Oral administration of 600 mg magnesium per day does not have an additive effect on restenosis, but may result in an improved clinical course. Large-scale studies with a higher dose of magnesium applied during angioplasty and for a longer period thereafter seems warranted.”